| Catalog No. | Size | Price (USD) |
| 40591-MM45-20 | 20 µg | $296.22 |
| 40591-MM45-100 | 100 µg | $592.44 |
General Information
| Product name | SARS-CoV-2 Spike Neutralizing Antibody, Mouse MAb |
| Validated applications | ELISA (FAQ Protocol), Neutralization |
| Application notes | (Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.) |
| Specificity | SARS-CoV-2 Spike RBD Protein (Could't block the binding between RBD and ACE2) Has cross-reactivity in ELISA with SARS-CoV-2 Omicron (LP.8.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H69) SARS-CoV-2 Omicron (KP.3.1.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H63) SARS-COV-2 Omicron (KP.3) Spike S1+S2 trimer Protein (Cat# 40589-V08H64) SARS-CoV-2 (XEC) Spike S1+S2 trimer Protein (Cat# 40589-V08H62) SARS-CoV-2 Omicron (XBB.1.16) Spike S1+S2 trimer Protein (Cat# 40589-V08H48) SARS-CoV-2 Omicron (XBB.1.5) Spike RBD Protein (Cat# 40592-V08H146) SARS-CoV-2 Omicron (XBB.1.5) Spike S1+S2 trimer Protein (Cat# 40589-V08H45) SARS-CoV-2 Omicron (XBB.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H42) SARS-CoV-2 Omicron (XBB) Spike RBD Protein (Cat# 40592-V08H144) SARS-CoV-2 Omicron (BQ.1.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H41) SARS-CoV-2 Omicron (BQ.1.1) Spike RBD Protein (Cat# 40592-V08H143) SARS-CoV-2 Omicron (BF.7) Spike S1+S2 trimer Protein (Cat# 40589-V08H39) SARS-CoV-2 Omicron (BA.4.6/BF.7) Spike RBD Protein (Cat# 40592-V08H140) SARS-CoV-2 Omicron (BA.4.6) Spike S1+S2 trimer Protein (Cat# 40589-V08H37) SARS-CoV-2 Omicron (BA.2.75) Spike RBD Protein (Cat# 40592-V08H135) SARS-CoV-2 Omicron (BA.2.75) Spike S1+S2 trimer Protein (Cat# 40589-V08H36) SARS-CoV-2 Omicron (BA.2.75.2) Spike RBD Protein (Cat# 40592-V08H141) SARS-CoV-2 Omicron (BA.2.75.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H38) SARS-CoV-2 Omicron (BA.2.3.20) Spike RBD Protein (Cat# 40592-V08H142) SARS-CoV-2 Omicron (BA.1.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H29) SARS-CoV-2 Omicron (B.1.1.529) S1+S2 trimer Protein (Cat# 40589-V08H26) SARS-CoV-2 Omicron (B.1.1.529) Spike S1 Protein (Cat# 40591-V08H41) SARS-CoV-2 Omicron (B.1.1.529) Spike RBD Protein (Cat# 40592-V08H121) SARS-CoV-2 Delta (B.1.617.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H10) SARS-CoV-2 Delta (B.1.617.2) Spike S1+S2 Protein (Cat# 40589-V08B16) SARS-CoV-2 Delta (B.1.617.2) Spike S1 Protein (Cat# 40591-V08H23) SARS-CoV-2 Delta (B.1.617.2) Spike RBD Protein (Cat# 40592-V08H90) SARS-CoV-2 Spike S1 Protein (Cat# 40591-V05H1) Medium cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.1.1) Spike RBD Protein (Cat# 40592-V08H129) SARS-CoV-2 Omicron (BA.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H28) SARS-CoV-2 Omicron (BA.2) Spike S1 Protein (Cat# 40591-V08H43) SARS-CoV-2 Omicron (BA.2.12.1) Spike RBD Protein (Cat# 40592-V08H132) SARS-CoV-2 XD(BA.1 x AY.4) Spike S1+S2 trimer Protein (Cat# 40589-V08H30) Minimal cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.2) Spike RBD Protein (Cat# 40592-V08H123) SARS-CoV-2 Omicron (BA.4) Spike RBD Protein (Cat# 40592-V08H130) SARS-CoV-2 Omicron (BA.5) Spike RBD Protein (Cat# 40592-V08H131) No cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.2) Spike S1 NTD Protein (Cat# 40591-V08H44) SARS-CoV-2 Delta (B.1.617.2) Spike S1 NTD Protein (Cat# 40591-V08H36) |
| Immunogen | Recombinant SARS-CoV-2 Spike S1 Protein (Catalog#40591-V05H1) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant SARS-CoV-2 Spike (Catalog#40591-V05H1; YP_009724390.1; Val16-Arg685). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #45 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Image / Experimental Information
| Image 1 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40591-MM45). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT)is 0.28 µg/mL. IC 50 (Omicron) is 5.19 µg/mL. IC 50 (Delta) is 1.71 µg/mL. |
| Image 1 Alt Text | SARS-CoV-2 Coronavirus spike Microneutralizaiton (MN) 33799 |
| Image 1 URL | Source image |
Background Information
| Description | The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2 (angiotensin-converting enzyme 2), DPP4 (dipeptidyl peptidase-4), APN (aminopeptidase N), CEACAM (carcinoembryonic antigen-related cell adhesion molecule), Sia (sialic acid), O-ac Sia (O-acetylated sialic acid). The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate. |
| References |
|
title: Toxicity study of SARS-CoV-2 Spike protein expressed on Bacillus subtilis spores.
authors: Atiqah Hazan; Amalia A Saperi; ...; Sazaly AbuBakar
journal: BMC microbiology
date: 2025-10-07
pmid: 41053546
cited_by_count: 1
techniques: Blocking Assay; Fluorescence; Incubation; Inverted Microscopy; Membrane; Microscopy; Negative Control; Plasmid Preparation; Positive Control; Recombinant; Western Blot
bioz_score: 93
title: SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance
authors: Carlota Fernandez-Antunez; Line A. Ryberg; ...; Maria Antonia De Francesco
journal: Viruses
date: 2025-07-29
doi: 10.3390/v17081055
cited_by_count: 0
techniques: Neutralization; Positive Control
bioz_score: 93
title: Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2
authors: Carina Metz; Verena Haug; ...; Pedro Plans-Rubió
journal: Vaccines
date: 2024-05-02
doi: 10.3390/vaccines12050492
pmcid: 11126055
cited_by_count: 8
techniques: Blocking Assay; Fluorescence; Immunofluorescence; Incubation; Infection; Microscopy; Software; Staining
bioz_score: 93
title: Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage
authors: Chung Park; Il-Young Hwang; ...; Diane M Harper
journal: eLife
date: 2024-03-20
pmid: 38507462
doi: 10.7554/eLife.86764
pmcid: 10954308
cited_by_count: 3
techniques: Binding Assay; Blocking Assay; Cell Culture; Expressing; Flow Cytometry; Imaging; Incubation; Luciferase; Plasmid Preparation; Recombinant; Saline; Staining; Transfection
bioz_score: 93
title: Microfluidic Enrichment of Intact SARS-CoV-2 Viral Particles by Stoichiometric Balanced DNA Computation.
authors: Yihao Huang; Qiuyue Wu; ...; Yanling Song
journal: ACS Nano
date: 2023-11-16
pmid: 37901936
doi: 10.1021/acsnano.3c08400
cited_by_count: 2
techniques: Isolation; Reverse Transcription
bioz_score: 93
title: Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.
authors: Mariana Pierre de Barros Gomes; José Henrique Rezende Linhares; ...; Sheila Maria Barbosa de Lima
journal: Viruses
date: 2023-07-31
pmid: 37515173
doi: 10.3390/v15071486
cited_by_count: 7
techniques: Bioprocessing; Comparison; Enzyme-linked Immunosorbent Assay; Produced; Sandwich ELISA; Virus
bioz_score: 93
title: A colorimetric lateral flow immunoassay based on oriented antibody immobilization for sensitive detection of SARS-CoV-2.
authors: Ae Sol Lee; Su Min Kim; ...; Chang Sup Kim
journal: Sensors and Actuators B: Chemical
date: 2023-03-15
pmid: 36589904
doi: 10.1016/j.snb.2022.133245
cited_by_count: 40
bioz_score: 94
title: Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay.
authors: Termsak Tantiwiwat; Apisitt Thaiprayoon; ...; Dujduan Waraho-Zhmayev
journal: Molecular biotechnology
date: 2023-03-02
pmid: 36103078
cited_by_count: 4
techniques: Binding Assay; Detection Assay
bioz_score: 93
title: Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
authors: Isabelle Montgomerie; Thomas W. Bird; ...; Lisa M. Connor
journal: iScience
date: 2023-02-20
pmid: 36845030
doi: 10.1016/j.isci.2023.106256
pmcid: 9940465
cited_by_count: 28
techniques: Activity Assay; Binding Assay; Comparison; Construct; FLAG-tag; Generated; Infection; Inhibition; Neutralization; Produced; Sequencing; Transgenic Assay; Variant Assay; Virus; Whisker Assay
bioz_score: 93
title: Methods and compositions for treating and preventing viral infection
authors: Jang Hyun Han; William J. Rutter; Mi-Young Seo
date: 2022-12-06
cited_by_count: 0
techniques: Infection; Inhibition; Neutralization; Virus
bioz_score: 93
title: Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking
authors: Jialu Zhang; Yunyun Xu; ...; Yanling Song
journal: Journal of the American Chemical Society
date: 2022-06-30
pmid: pm35770902
cited_by_count: 0
techniques: CCK-8 Assay; High Performance Liquid Chromatography; Marker; Modification; Purification; Red Blood Cell Lysis; Synthesized
bioz_score: 94
title: Polymerized Porin as a Novel Delivery Platform for Coronavirus Vaccine
authors: Zhongqian Yang; Liangqun Hua; ...; Yanbing Ma
journal: Europe PMC
date: 2021-12-27
doi: 10.21203/rs.3.rs-1128338
cited_by_count: 0
techniques: Binding Assay; Imaging; In Vivo; Incubation; Microscopy; Staining; Transmission Assay; Transmission Electron Microscopy
bioz_score: 93
title: Fatal neuroinvasion and SARS-CoV-2 tropism in K18-hACE2 mice is partially independent on hACE2 expression
authors: Carossino Mariano; Montanaro Paige; ...; Crossland Nicholas A.
journal: bioRxiv
date: 2021-09-23
cited_by_count: 0
techniques: Activity Assay; Derivative Assay; Infection; Injection; Isolation; Labeling; Multiplex Assay; Neutralization; Optical Imaging; Positive Control; Software; Transformation Assay
bioz_score: 93
title: Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
authors: Ester Lopez; Ebene R. Haycroft; ...; Amy W. Chung
journal: JCI insight
date: 2021-08-23
pmid: 34251356
doi: 10.1172/jci.insight.150012
pmcid: 8409985
cited_by_count: 30
techniques: Binding Assay; Expressing; Generated; Infection; Inhibition; Isolation; Microneutralization Assay; Multiplex Assay; Purification; Synthesized; Variant Assay
bioz_score: 93
title: Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.
authors: So-Hee Hong; Hanseul Oh; ...; Jae-Hwan Nam
journal: Science Advances
date: 2021-06-08
pmid: 34049881
cited_by_count: 26
techniques: Binding Assay; Concentration Assay; Purification; Recombinant; Sequencing
bioz_score: 93
title: Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay
authors: Lopez Ester; Haycroft Ebene R.; ...; Chung Amy W.
journal: medRxiv
date: 2021-03-26
doi: 10.1101/2021.03.20.21254037
cited_by_count: 0
techniques: Binding Assay; Blocking Assay; Clone Assay; Expressing; Generated; Infection; Inhibition; Isolation; Microneutralization Assay; Multiplex Assay; Plasmid Preparation; Purification; Recombinant; Size-exclusion Chromatography; Transfection; Variant Assay
bioz_score: 93
title: Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein
authors: James Ropa; Scott Cooper; ...; Hal E. Broxmeyer
journal: Stem cell reviews and reports
date: 2020-10-21
pmid: 33089452
doi: 10.1007/s12015-020-10056-z
pmcid: 7577648
cited_by_count: 53
techniques: Ex Vivo; Expressing; Flow Cytometry; Fluorescence; Incubation; Infection; Recombinant; Staining
bioz_score: 93
